Oral misoprostol solution (Cytotec) vs. tablet (Angusta) efficacy for labor induction compared in Phase 4 trial
Background
Labor induction is a common obstetric procedure, often requiring pharmacologic cervical ripening. Misoprostol, a synthetic prostaglandin E1 analog, is widely used for this purpose due to its uterotonic and cervical ripening properties. While an oral tablet formulation, Angusta®, is specifically approved for labor induction, an off-label oral solution prepared from Cytotec® tablets is also frequently used. A substantial cost disparity exists, with Angusta® being approximately 43 times more expensive than Cytotec®, prompting investigation into whether the more affordable Cytotec® can serve as an equally effective alternative.
Study Design
The MISOBEST study was a Phase 4 clinical trial (NCT02777190) designed to compare two oral misoprostol formulations for labor induction. The study enrolled a total of 34 participants. It aimed to evaluate the efficacy of cervical ripening when administering misoprostol as an oral tablet (Angusta®) versus an off-label oral solution prepared from misoprostol tablets (Cytotec®). The primary endpoint was the efficacy of cervical ripening, though specific metrics were not detailed. The trial was terminated, and no further methodological details like exact doses, frequency, or duration were provided in the abstract.
Results
No results or findings were reported in the provided abstract or study description for this terminated Phase 4 clinical trial. The study's aim was to evaluate the comparative efficacy of two misoprostol formulations for labor induction, but no data on cervical ripening, delivery outcomes, or any other endpoints were presented. Therefore, no specific numbers, p-values, or fold-changes can be extracted or reported from this record.
Why It Matters
Understanding the comparative efficacy of misoprostol formulations is crucial for optimizing labor induction protocols and healthcare resource allocation. If the significantly cheaper Cytotec® solution proves to be non-inferior to the expensive Angusta® tablet for cervical ripening and labor induction, it could lead to substantial cost savings for healthcare systems globally. This would directly impact clinical practice by potentially shifting standard protocols towards a more economical yet equally effective option. Without reported findings, however, no definitive changes to current protocols can be recommended, highlighting the need for completed studies with published results.
